Abstract
Distant metastasis is the leading cause of cancer-related mortality, yet how tumor-intrinsic metabolic enzymes regulate tumor-immune crosstalk during metastasis remains poorly understood. Using an in vivo CRISPR-Cas9 screen targeting metabolic genes in an orthotopic 4T1 mammary carcinoma model, we identified arginase 2 (ARG2) as a lymphocyte-dependent suppressor of lung metastasis. Loss of ARG2 enhanced spontaneous lung metastasis without affecting primary tumor growth or metastatic outgrowth following intravenous tumor cell injection, indicating a role in early metastatic dissemination. Mechanistically, ARG2 deficiency increased nitric oxide synthase 2 (NOS2) expression, nitric oxide production, cytosolic DNA accumulation, and activation of the cGAS-STING-NF-κB pathway, leading to inflammatory cytokine production. ARG2-deficient tumors exhibited enrichment of Th17 cells and reduced anti-tumor immune populations. Genetic deletion of NOS2 reversed these immune alterations and suppressed metastasis. Together, these findings identify a tumor cell-intrinsic ARG2-NOS2 axis that promotes metastasis through inflammatory remodeling of the tumor microenvironment.